ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.
Future Oncol
; 15(3): 231-239, 2019 Jan.
Article
em En
| MEDLINE
| ID: mdl-30362375
ABSTRACT
Lurbinectedin is an inhibitor of active transcription of protein-coding genes, causing DNA-break accumulation, apoptosis and modulation of the tumor microenvironment. Early-phase clinical trials indicate promising activity of lurbinectedin in small-cell lung cancer. Here, we describe the rationale and design of ATLANTIS (NCT02566993), an open-label, randomized, multicenter Phase III study to compare the efficacy of lurbinectedin and doxorubicin combination with standard-of-care chemotherapy, investigator's choice of cyclophosphamide/doxorubicin/vincristine or topotecan, in patients with small-cell lung cancer that has progressed following one line of platinum-based chemotherapy. Patients are randomized in a 11 ratio. The primary end point is overall survival and key secondary end points include progression-free survival, best tumor response and duration of response, each assessed by independent review committee.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Carbolinas
/
Doxorrubicina
/
Carcinoma de Pequenas Células do Pulmão
/
Microambiente Tumoral
/
Compostos Heterocíclicos de 4 ou mais Anéis
Tipo de estudo:
Clinical_trials
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Estados Unidos